[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642183":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":17,"centralContacts":39,"locations":45,"responsibleParty":75,"collaborators":17,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":17,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":17,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":17,"overallStatus":48,"whyStopped":17,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Corxel Pharmaceuticals","INDUSTRY",[8,14,20,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo group","PLACEBO_COMPARATOR","Placebo",[13],"Other: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"CX11 Group A","EXPERIMENTAL",null,[19],"Drug: CX11",{"label":21,"type":16,"description":17,"interventionNames":22},"CX11 Group B",[19],{"label":24,"type":16,"description":17,"interventionNames":25},"CX11 Group C",[19],[27,32,36],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":17},"DRUG","CX11","CX11 tablets administered orally once daily (QD) with meals",[15,21,24],{"type":33,"name":11,"description":34,"armGroupLabels":35,"otherNames":17},"OTHER","Matching placebo tablets administered orally once daily (QD) with meals",[9],{"type":28,"name":29,"description":37,"armGroupLabels":38,"otherNames":17},"CX11 tablets administered orally once daily (QD) with high fat, high calorie meal",[15,21,24],[40],{"name":41,"role":42,"phone":43,"phoneExt":17,"email":44},"Study coordinator","CONTACT","201-268-3723","information.center@corxelbio.com",[46,63],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Corxel Investigational site","RECRUITING","Las Vegas","Nevada","89113","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-115.13722,36.17497,{"lat":58,"lon":57},[61],{"name":62,"role":42,"phone":43,"phoneExt":17,"email":44},"Study Director",{"facility":64,"status":48,"city":65,"state":66,"zip":67,"country":52,"countryCode":53,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Corxel Investigational Site","Austin","Texas","78744",{"type":55,"coordinates":69},[70,71],-97.74306,30.26715,{"lat":71,"lon":70},[74],{"name":62,"role":42,"phone":43,"phoneExt":17,"email":44},{"type":76,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100642183","phase-1-a-study-to-evaluate-the-safety-and-tolerability-of-different-doses-of-cx11-tablets-100642183",false,"NCT07652047","A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets","A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities","Inclusion Criteria:\n\n* Male or female, 18-55 years.\n* BMI ≥30.0 to ≤39.9 kg\u002Fm², or ≥27.0 to \\\u003C30.0 kg\u002Fm² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea.\n* Prior unsuccessful diet\u002Fexercise weight-loss attempt and stable body weight within 90 days.\n* Able to comply with study procedures and reproductive requirements.\n\nExclusion Criteria:\n\n* Diabetes or obesity due to endocrine\u002Fgenetic causes.\n* Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery\u002Fdevice, or investigational treatment.\n* Significant cardiovascular, ECG\u002FQT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks.\n* Personal\u002Ffamily history of medullary thyroid carcinoma or multiple endocrine neoplasia.\n* Pregnancy, breastfeeding, recent nicotine\u002Fdrug use, excessive alcohol use, or any condition\u002Fmedication making participation inappropriate.","FEMALE","18 Years","55 Years",{"count":88,"type":89},90,"ESTIMATED","INTERVENTIONAL",[92],"PHASE1","A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.",[95],"Obesity & Overweight","2026-06-15",{"date":98,"type":99},"2026-06-17","ACTUAL",{"date":101,"type":99},"2026-05-11",{"date":103,"type":89},"2027-06",{"name":5,"class":6},2]